

## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 19 February 2004 (19.02.2004)

PCT

## (10) International Publication Number WO 2004/015070 A3

(51) International Patent Classification7: C12P 19/34

G01N 33/53,

(21) International Application Number:

PCT/US2003/024548

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/402,521

8 August 2002 (08.08.2002) US

- (71) Applicants (for all designated States except US): BAY-LOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, Houston, TX.77030 (US). OPEXA PHARMA-CEUTICALS INC. [US/US]; 835 Green Parkway, Suite 150, Houston, TX 77067 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): ZHANG, Jingwu, Z. [US/US]; 2219 Parkview Lane, Missouri City, TX 77459 (US).
- (74) Agents: CLOUGH, David, W. et al.; Katten Muchin Zavis Rosenman, 525 W. Monroe Street, Suite 1600, Chicago, IL 60661-3693 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 11 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ISOLATION AND IDENTIFICATION OF T CELLS

(57) Abstract: The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention is further directed to the diagnosis of T cell associated diseases.





04FEB 2005

10/524300

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/24548

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : G01N 33/53; C12P 19/34										
TIS CT 424/7.21. 93.7: 435/91.2										
According to International Patent Classification (IPC) or to both national classification and IPC  B. FIELDS SEARCHED										
		. eleccificat	ion membols)							
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/7.21, 93.7; 435/91.2										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched										
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet										
C. DOCT	IMENTS CONSIDERED TO BE RELEVANT									
Category *	Citation of document, with indication, where ap	propriate, o	of the relevant passages	Relevant to claim No.						
Y	HERMANS et al. Cytokine Profile of Myelin Basic Protein-Reactive T Cells in Mutiple Sclerosis and Healthy Individuals. Annals of Neurology. 1997, Vol. 42, No. 1, pages 18- 27, see entire article.									
Y	ZHANG et al. Th2 immune regulation induced by T sclerosis. European Journal of Immunology. March entire article.	1-30								
Y	US 6,303,314 B1 (ZHANG, J. Z.) 16 October 2001	1-30								
	•									
Further	documents are listed in the continuation of Box C.		See patent family annex.							
Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier application or patent published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to		"X"	date and not in conflict with the appli- principle or theory underlying the inv document of particular relevance; the considered novel or cannot be considered when the document is taken alone							
establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art								
		"& <b>"</b>	document member of the same patent							
"P" document published prior to the international filing date but later than the priority date claimed			nailing of the international sear							
Date of the actual completion of the international search			1	O SEP 2004						
09 April 2004 (09.04.2004)  Name and mailing address of the ISA/US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (703)305-3230			ed officed Library e DiBruio, Phys. e No. 571-272-1600	SEP 2004 LINCE You						

Form PCT/ISA/210 (second sheet) (July 1998)





PCT	/US03	/24548

Continuati	on of B.	FIEL	09 9EA	KCDED I	tem 3:	
WEST 2 1						, SCIS

WEST 2.1, STN(EMBASE, BIOSIS, MEDLINE, CAPLUS, SCISEARCH, PROMT, BIOBUSINESS) search terms: inventor's name, cd69, cd4, cd25, hla-dr, il-2, il-5, il-10, il-13, ifn-g, tnfa, cd36, autoantigens, autoimmunity, treat/ment, myelin basic protein, mbp, activated T cells, 83-99, 151-170.

Form PCT/ISA/210 (second sheet) (July 1998)